Hexarelin

Overview

Hexarelin is a synthetic peptide belonging to the class of growth hormone secretagogues, compounds that stimulate the body's own release of growth hormone (GH). It is a member of the growth hormone-releasing peptide (GHRP) family and is structurally related to compounds such as GHRP-6. Hexarelin is notable for being one of the more potent secretagogues studied, and it has been of interest both for its effects on GH and for actions on the cardiovascular system that appear partly independent of growth hormone.

Despite this scientific attention, hexarelin is not an approved medicine. It is used as a research chemical and is sold through unregulated channels, where it is marketed for muscle growth, recovery, and anti-aging without the support of completed human efficacy trials. It is also prohibited in competitive sport.

A defining practical feature of hexarelin is desensitization: with continued exposure, the GH response tends to diminish over time. This phenomenon complicates any sustained use and is an important consideration distinguishing it from secretagogues with more durable effects.

How it works

Hexarelin works mainly by activating the growth hormone secretagogue receptor (GHS-R), the same receptor targeted by the natural hormone ghrelin. Stimulating this receptor in the pituitary gland and hypothalamus triggers a pulse of growth hormone release. Because it acts through this endogenous pathway rather than supplying GH directly, hexarelin amplifies the body's own secretion, which then leads to downstream production of insulin-like growth factor 1 (IGF-1).

A distinctive aspect of hexarelin is its interaction with CD36, a scavenger receptor found in cardiovascular tissue. Through CD36 and related pathways, hexarelin has shown direct cardiac and vascular effects in experimental models, including potential cardioprotective actions, that do not appear to depend solely on growth hormone. This has made it a subject of interest in cardiovascular research distinct from its endocrine role.

The previously mentioned desensitization arises because repeated, strong stimulation of the GHS-R can downregulate the response, reducing GH output over time. This receptor-level adaptation is a key mechanistic limitation, meaning that the pronounced acute effects seen with hexarelin do not necessarily translate into sustained elevation of growth hormone with ongoing exposure.

Research & evidence

Hexarelin has been investigated primarily in pharmacological and physiological studies examining its ability to stimulate growth hormone release and its effects on cardiovascular tissue. In short-term human studies, it reliably provoked GH secretion, which is what established it as a potent secretagogue. Researchers have also explored its cardiac actions in preclinical models, where CD36-mediated effects suggested possible protective roles in heart tissue.

However, the body of evidence falls well short of what would be needed to support therapeutic use. There are no large, completed clinical trials demonstrating that hexarelin safely produces meaningful benefits for muscle growth, body composition, aging, or heart disease in patients. Much of the interest in performance and physique contexts is extrapolated from acute GH-release data and from animal studies rather than from controlled outcomes in humans.

The desensitization observed with repeated dosing further limits the practical and scientific case for sustained use, since the GH response wanes. Overall, hexarelin should be understood as an investigational and research-grade compound whose interesting pharmacology has not been converted into demonstrated, approved clinical value.

Safety & legal status

Because hexarelin has not undergone comprehensive clinical development, its long-term safety in humans is not well characterized. Potential concerns common to growth hormone secretagogues include effects on blood sugar and insulin sensitivity, increases in the hormone cortisol and prolactin, and water retention. Stimulating growth hormone and IGF-1 also raises theoretical concerns about unwanted tissue growth, which unsupervised use does not address.

Its potent activation of the ghrelin receptor can also influence appetite and other ghrelin-mediated functions, and the desensitization phenomenon means that effects and tolerability may change with continued exposure. Products sold as hexarelin are research chemicals of uncertain purity and concentration, adding the further risks of contamination and inaccurate labeling that accompany unregulated peptides.

Hexarelin is not approved for human use by major regulatory agencies, and it is prohibited at all times under World Anti-Doping Agency rules as a growth hormone secretagogue. Athletes face sanctions for its use, and the broader lack of regulatory oversight means buyers have no assurance of quality or safety. It should be regarded strictly as an experimental compound rather than a therapeutic option.

Frequently asked questions

References

Each source links to its original record — peer-reviewed studies, regulator pages, or reference texts, labelled by type. We summarize findings neutrally; a citation is a reference, not an endorsement, and not a claim that its authors reviewed this page.

1. Tivesten A, Bollano E, Caidahl K, et al. The growth hormone secretagogue hexarelin improves cardiac function in rats after experimental myocardial infarction. Endocrinology. 2000. Peer-reviewed study
2. Mao Y, Tokudome T, Kishimoto I. Hexarelin protects cardiomyocytes from ischemia/reperfusion injury through the interleukin-1 signaling pathway. Int Heart J. 2017. Peer-reviewed study
3. Mao Y, Tokudome T, Kishimoto I. The cardiovascular action of hexarelin. J Geriatr Cardiol. 2014. Peer-reviewed study
4. Guan C, Li C, Shen X, et al. Hexarelin alleviates apoptosis on ischemic acute kidney injury via MDM2/p53 pathway. Eur J Med Res. 2023. Peer-reviewed study
5. Jiang B, Wang M, Li X, et al. Hexarelin attenuates abdominal aortic aneurysm formation by inhibiting SMC phenotype switch and inflammasome activation. Microvasc Res. 2022. Peer-reviewed study
6. Mosa RM, Zhang Z, Shao R, et al. Implications of ghrelin and hexarelin in diabetes and diabetes-associated heart diseases. Endocrine. 2015. Peer-reviewed study